Novavax, Inc. splits its revenue into 8 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Nuvaxovid Sales at $625.2 million, 56% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
412
|
1,123
|
682
|
984
|
1,982
|
1,146
|
476
|
19
|
34
|
31
|
15
|
| Product |
—
|
—
|
—
|
—
|
1,555
share 78.5%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Nuvaxovid Sales |
29
-95.6%
share 7.1%
|
625
+228.7%
share 55.6%
|
190
-64.2%
share 27.9%
|
531
share 54.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Licensing Royalties And Other |
286
-20.5%
share 69.4%
|
438
-6.5%
share 39.0%
|
469
+5421.7%
share 68.7%
|
8
-80.7%
share 0.9%
|
44
-77.7%
share 2.2%
|
198
+782.5%
share 17.2%
|
22
+721.6%
share 4.7%
|
3
share 14.6%
|
—
|
—
|
—
|
| Grant |
—
|
—
|
—
|
427
+11.6%
share 43.4%
|
383
-59.6%
share 19.3%
|
949
+109.3%
share 82.8%
|
453
+2743.8%
share 95.3%
|
16
share 85.4%
|
—
|
—
|
—
|
| License Fees And Sales Based Royalties |
—
|
—
|
398
share 58.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Supply Sales |
97
+94.7%
share 23.5%
|
60
+160.3%
share 5.3%
|
23
share 3.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Milestone Payments |
—
|
—
|
—
|
—
|
20
+0.0%
share 1.0%
|
20
share 1.7%
|
—
|
—
|
—
|
—
|
—
|
| Sales Based Royalties |
—
|
—
|
—
|
8
-5.6%
share 0.9%
|
9
-95.0%
share 0.5%
|
179
share 15.6%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- NVAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1000694
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.